Cash and cash equivalents $3,796,000 $5,730,000
Short term investments 26,695,000 27,649,000
Accounts receivable, net 3,103,000 3,226,000
Inventories, net 5,105,000 5,046,000
Other current assets 211,000 415,000
Total current assets 38,910,000 42,066,000
Equipment, net 1,694,000 1,602,000
Other assets 77,000 122,000
$40,681,000 $43,790,000
LIABILITIES AND STOCKHOLDER'S EQUITY
Current liabilities:
Accounts payable $1,640,000 $2,074,000
Other current liabilities 2,532,000 2,233,000
Total current liabilities 4,172,000 4,307,000
Long-term liabilities 1,327,000 1,671,000
Stockholders' equity 35,182,000 37,812,000
$40,681,000 $43,790,000
THERMOGENESIS CORP.
Condensed Statements of Operations
(Unaudited)
Three Months Ended Six Months Ended
December 31, December 31,
2007 2006 2007 2006
Net revenues $5,487,000 $3,716,000 $9,119,000 $8,021,000
Cost of revenues 3,577,000 2,927,000 6,000,000 5,520,000
Gross profit 1,910,000 789,000 3,119,000 2,501,000
Expenses:
Selling, general
and
administrative 2,357,000 2,300,000 4,777,000 4,612,000
Resear
'/>"/>
SOURCE ThermoGenesis Corp. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 Related biology technology :1.
ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal Year 2007 on September 12, 20072.
ThermoGenesis Corp. Reports Fourth Quarter and Fiscal Year 2007 Results3.
ThermoGenesis Corp. to Present at 2007 Global Life Sciences Conference on Thursday, September 27, 20074.
ThermoGenesis Corp. to Announce First Quarter Fiscal 2008 Results on November 8, 20075.
ThermoGenesis Corp. to Announce Second Quarter Fiscal 2008 Results on February 6, 20086.
Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.7.
Michael Troullis Appointed Chief Financial Officer of Quintiles Transnational Corp.8.
MAKO Surgical Corp. Files Registration Statement for Initial Public Offering of Common Stock9.
CellCyte Genetics Corp. Forms Device Division to Develop and Manufacture Stem Cell Cultivation and Replication Products10.
Helix BioPharma Corp. announces fiscal 2007 results11.
Patent on Technology for the Delivery of Stem Cells to the Human Heart Issued to CellCyte Genetics Corp. of Washington